The U.S. Food and Drug Administration today approved Epidiolex (cannabidiol) [CBD] oral solution for the treatment of seizures associated with two rare and severe forms of epilepsy, Lennox-Gastaut syndrome and Dravet syndrome, in patients two years of age and older. This is the first FDA-approved drug that contains a purified drug substance derived from marijuana. It is also the first FDA approval of a drug for the treatment of patients with Dravet syndrome.
I can recall just 6 years ago attending Investigators Meetings, where the lead medical directors would tell the Principal Investigators, marijuana does not treat epilepsy, but only masks the symptoms.
It's very cool to see such progress in getting additional therapeutic treatments to patients.
This is pretty amazing news.
The U.S. Food and Drug Administration today approved Epidiolex (cannabidiol) [CBD] oral solution for the treatment of seizures associated with two rare and severe forms of epilepsy, Lennox-Gastaut syndrome and Dravet syndrome, in patients two years of age and older. This is the first FDA-approved drug that contains a purified drug substance derived from marijuana. It is also the first FDA approval of a drug for the treatment of patients with Dravet syndrome.
I can recall just 6 years ago attending Investigators Meetings, where the lead medical directors would tell the Principal Investigators, marijuana does not treat epilepsy, but only masks the symptoms.
It's very cool to see such progress in getting additional therapeutic treatments to patients.
#fuckyes!
Cheers!
@massmedicinals